The deubiquitinating enzyme UCHL3 promotes anaplastic thyroid cancer progression and metastasis through Hippo signaling pathway

Cell Death Differ. 2023 May;30(5):1247-1259. doi: 10.1038/s41418-023-01134-z. Epub 2023 Feb 22.

Abstract

Yes-associated protein (YAP) is one of major key effectors of the Hippo pathway and the mechanism supporting abnormal YAP expression in Anaplastic thyroid carcinoma (ATC) remains to be characterized. Here, we identified ubiquitin carboxyl terminal hydrolase L3 (UCHL3) as a bona fide deubiquitylase of YAP in ATC. UCHL3 stabilized YAP in a deubiquitylation activity-dependent manner. UCHL3 depletion significantly decreased ATC progression, stem-like and metastasis, and increased cell sensitivity to chemotherapy. Depletion of UCHL3 decreased the YAP protein level and the expression of YAP/TEAD target genes in ATC. UCHL3 promoter analysis revealed that TEAD4, through which YAP bind to DNA, activated UCHL3 transcription by binding to the promoter of UCHL3. In general, our results demonstrated that UCHL3 plays a pivotal role in stabilizing YAP, which in turn facilitates tumorigenesis in ATC, suggesting that UCHL3 may prove to be a potential target for the treatment of ATC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hippo Signaling Pathway
  • Humans
  • TEA Domain Transcription Factors
  • Thyroid Carcinoma, Anaplastic* / genetics
  • Thyroid Neoplasms* / genetics
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • Ubiquitin Thiolesterase / genetics
  • Ubiquitin Thiolesterase / metabolism

Substances

  • Transcription Factors
  • Ubiquitin Thiolesterase
  • TEAD4 protein, human
  • TEA Domain Transcription Factors
  • UCHL3 protein, human